JP2009522339A5 - - Google Patents

Download PDF

Info

Publication number
JP2009522339A5
JP2009522339A5 JP2008549020A JP2008549020A JP2009522339A5 JP 2009522339 A5 JP2009522339 A5 JP 2009522339A5 JP 2008549020 A JP2008549020 A JP 2008549020A JP 2008549020 A JP2008549020 A JP 2008549020A JP 2009522339 A5 JP2009522339 A5 JP 2009522339A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
inhibitor
blocks
maturation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008549020A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009522339A (ja
Filing date
Publication date
Priority claimed from PCT/EP2006/050060 external-priority patent/WO2007077042A1/en
Application filed filed Critical
Publication of JP2009522339A publication Critical patent/JP2009522339A/ja
Publication of JP2009522339A5 publication Critical patent/JP2009522339A5/ja
Pending legal-status Critical Current

Links

JP2008549020A 2006-01-06 2007-01-08 痛風または偽痛風の新規な治療法 Pending JP2009522339A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/EP2006/050060 WO2007077042A1 (en) 2006-01-06 2006-01-06 New method for the treatment of gout or pseudogout
US11/539,851 US20070161559A1 (en) 2006-01-06 2006-10-09 Method for the treatment of gout or pseudogout
PCT/EP2007/050143 WO2007077261A1 (en) 2006-01-06 2007-01-08 New method for the treatment of gout or pseudogout

Publications (2)

Publication Number Publication Date
JP2009522339A JP2009522339A (ja) 2009-06-11
JP2009522339A5 true JP2009522339A5 (cg-RX-API-DMAC7.html) 2010-02-25

Family

ID=35998432

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008549020A Pending JP2009522339A (ja) 2006-01-06 2007-01-08 痛風または偽痛風の新規な治療法

Country Status (3)

Country Link
US (4) US20070161559A1 (cg-RX-API-DMAC7.html)
JP (1) JP2009522339A (cg-RX-API-DMAC7.html)
WO (2) WO2007077042A1 (cg-RX-API-DMAC7.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0718469A2 (pt) * 2006-10-20 2014-01-21 Regeneron Pharma Uso de um antagonista de interleucina 1 (il-1), método para tratar, inibir, ou melhorar pseudogota, uso de um ou mais agentes terapêuticos, e, produto.
US7632490B2 (en) * 2006-10-20 2009-12-15 Regeneron Pharmaceuticals, Inc. Use of IL-1 antagonists to treat gout
BRPI0819847B1 (pt) 2007-11-27 2022-01-11 Ardea Biosciences, Inc Compostos e composições
RU2018100129A (ru) * 2007-12-20 2019-02-20 Ксома (Сша) Ллс Способы лечения подагры
EP2300000A1 (en) * 2008-07-03 2011-03-30 University of Massachusetts Methods and compositions for reducing inflammation and treating inflammatory disorders
US8242154B2 (en) 2008-09-04 2012-08-14 Ardea Biosciences, Inc. Compounds, compositions and methods of using same for modulating uric acid levels
EP2165705A1 (en) * 2008-09-18 2010-03-24 Centre National de la Recherche Scientifique (CNRS) Use of a compound capable of reducing the uric acid level for the prevention and/or the treatment of lung inflammation and fibrosis
TWI500427B (zh) 2010-05-14 2015-09-21 Abbvie Inc Il-1結合蛋白
EP2857499A1 (en) 2010-10-01 2015-04-08 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
WO2012078101A1 (en) * 2010-12-07 2012-06-14 Swedish Orphan Biovitrum Ab (Publ) Method for the treatment of il-1 mediated diseases
ES2578477T3 (es) * 2011-03-11 2016-07-27 Roche Diagniostics Gmbh ASC como marcador de la enfermedad pulmonar obstructiva crónica (EPOC)
JP6313203B2 (ja) * 2011-07-18 2018-04-18 ユニバーシティー オブ ケンタッキー リサーチ ファウンデイションUniversity Of Kentucky Research Foundation Alu−rna誘導変性からの細胞の保護及び細胞保護用阻害剤
US9707235B1 (en) 2012-01-13 2017-07-18 University Of Kentucky Research Foundation Protection of cells from degeneration and treatment of geographic atrophy
EA201492184A1 (ru) 2012-05-25 2015-07-30 Берг Ллк Способы лечения метаболического синдрома путем модулирования белка теплового шока (hsp) 90-бета
WO2015188198A2 (en) 2014-06-06 2015-12-10 Berg Llc Methods of treating a metabolic syndrome by modulating heat shock protein (hsp) 90-beta
US9938528B2 (en) * 2014-12-11 2018-04-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods and pharmaceutical compositions for treating human immunodeficiency virus type 1 (HIV-1) infections
CA2986702C (en) 2015-05-21 2023-04-04 David Wang Modified demineralized cortical bone fibers
US10527614B2 (en) * 2015-11-09 2020-01-07 Bio-Rad Laboratories, Inc. Assays using avidin and biotin
US20200315540A1 (en) * 2016-12-14 2020-10-08 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an il-1 inhibitor
US12566174B2 (en) 2017-05-11 2026-03-03 The Research Foundation For The State University Of New York Method and kit for determining the presence of monosodium urate crystals in joint synovial fluid
GB201815045D0 (en) 2018-09-14 2018-10-31 Univ Ulster Bispecific antibody targeting IL-1R1 and NLPR3
CN111067911A (zh) * 2018-10-18 2020-04-28 刘琦 白头翁皂苷b4抗急性痛风性关节炎的医药用途
US20240158490A1 (en) * 2022-11-11 2024-05-16 Jeff R. Peterson Gout flare prevention methods using il-1beta blockers
US12269875B2 (en) 2023-08-03 2025-04-08 Jeff R. Peterson Gout flare prevention methods using IL-1BETA blockers

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6511665B1 (en) * 1987-11-25 2003-01-28 Immunex Corporation Antibodies to interleukin-1 receptors
US5872095A (en) * 1990-05-01 1999-02-16 Chiron Corporation IL-1 receptor antagonists medicaments
DE69700616T2 (de) * 1996-07-02 2000-03-16 Nisshin Flour Milling Co., Ltd. Imid derivate
JPH1072421A (ja) * 1996-07-02 1998-03-17 Nisshin Flour Milling Co Ltd イミド誘導体
US6770647B2 (en) * 2001-08-17 2004-08-03 Bristol-Myers Squibb Pharma Company Bicyclic hydroxamates as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE)
AU2003208946A1 (en) * 2002-02-28 2003-09-16 Eli Lilly And Company Anti-interleukin-1 beta analogs

Similar Documents

Publication Publication Date Title
Becker Pain management: Part 1: Managing acute and postoperative dental pain
Doan et al. Rheumatoid arthritis: an overview of new and emerging therapies
WO2007002543A8 (en) Antibody formulations having optimized aggregation and fragmentation profiles
US9149499B1 (en) Cannabis based therapeutic and method of use
Schlesinger Anti-interleukin-1 therapy in the management of gout
IL193444A (en) Isolated reactive monoclonal antibody that binds both IL-17a and IL-17f, an isolated serum containing it, a diagnostic kit containing it, a pharmaceutical product containing it, and its use as a drug to treat or prevent inflammation or inflammatory disease.
JP2023506147A5 (cg-RX-API-DMAC7.html)
JP2017079785A5 (cg-RX-API-DMAC7.html)
JP2005533005A5 (cg-RX-API-DMAC7.html)
JP2007530577A5 (cg-RX-API-DMAC7.html)
WO2007096151A3 (en) Inhibitors of p38-kinase for treatment of pulmonary hypertension
JP2013512280A5 (cg-RX-API-DMAC7.html)
JP2013521303A5 (cg-RX-API-DMAC7.html)
CN105050624A (zh) 利用阿普斯特来治疗银屑病关节炎的方法
JP2013544244A5 (cg-RX-API-DMAC7.html)
JP2008509137A5 (cg-RX-API-DMAC7.html)
KR20100099178A (ko) P2x7 조절제로서의 5-옥소-3-피롤리딘카르복스아미드 유도체
JP2010511631A5 (cg-RX-API-DMAC7.html)
JP2008543936A5 (cg-RX-API-DMAC7.html)
JP2005533104A5 (cg-RX-API-DMAC7.html)
Betrains et al. Efficacy and safety of canakinumab treatment in schnitzler syndrome: A systematic literature review
JP2008516970A5 (cg-RX-API-DMAC7.html)
JP2008505107A5 (cg-RX-API-DMAC7.html)
TW200902027A (en) Compositions and methods for treating medical conditions
JP2021506778A5 (cg-RX-API-DMAC7.html)